Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C3H7NO2 |
| Molecular Weight | 89.0932 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCOC(N)=O
InChI
InChIKey=JOYRKODLDBILNP-UHFFFAOYSA-N
InChI=1S/C3H7NO2/c1-2-6-3(4)5/h2H2,1H3,(H2,4,5)
| Molecular Formula | C3H7NO2 |
| Molecular Weight | 89.0932 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/29329860Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/28818685 | https://www.ncbi.nlm.nih.gov/pubmed/18921082 https://www.ncbi.nlm.nih.gov/pubmed/2188890
Sources: https://www.ncbi.nlm.nih.gov/pubmed/29329860
Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/28818685 | https://www.ncbi.nlm.nih.gov/pubmed/18921082 https://www.ncbi.nlm.nih.gov/pubmed/2188890
Urethane (Ethyl carbamate) is is an ethyl ester of carbamic acid, that has been found in many fermented food products and alcoholic beverages such as cheese, bread, yogurt, wine, whiskey, soya sauce etc. An in vitro study indicated that Urethane has a potential to inhibit the growth of bacteria, plant tissue, and rat carcinoma. Urethane has been used for many years as an antineoplastic agent for medical purposes but this application ended after it was discovered to be carcinogenic in 1943. Urethane can produce long-lasting anesthesia without affecting blood gases or blood pressure, it has been used in acute studies. In earlier studies, Urethane was also used as a co-solvent for water-insoluble analgesic and sedative drugs in Japan. By US FDA regulations, ethyl carbamate has been withdrawn from pharmaceutical use. However, small quantities of ethyl carbamate are also used in laboratories as an anesthetic for animals.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2311221 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11848977 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | URETHANE Approved UseUnknown |
|||
| Primary | URETHANE Approved UseUnknown |
Doses
| Dose | Population | Adverse events |
|---|---|---|
0.5 g 3 times / day multiple, oral Studied dose Dose: 0.5 g, 3 times / day Route: oral Route: multiple Dose: 0.5 g, 3 times / day Sources: |
unhealthy, 2 year |
Other AEs: Vomiting, White blood cell increased... Other AEs: Vomiting (1 patient) Sources: White blood cell increased (grade 5, 1 patient) Hemorrhage (grade 5, 1 patient) |
10 % multiple, topical |
unhealthy, 21 years |
Other AEs: Nausea, Vomiting... Other AEs: Nausea (1 patient) Sources: Vomiting (1 patient) Leukopenia (grade 5, 1 patient) Hemorrhage (grade 5, 1 patient) Renal disorder NOS (grade 5, 1 patient) Liver injury (grade 5, 1 patient) |
6 g 1 times / day multiple, oral Studied dose Dose: 6 g, 1 times / day Route: oral Route: multiple Dose: 6 g, 1 times / day Sources: |
unhealthy, 51-76 years Health Status: unhealthy Age Group: 51-76 years Sex: M+F Sources: |
Other AEs: Anorexia, Leukopenia... Other AEs: Anorexia (4 patients) Sources: Leukopenia (1 patient) Weight loss (severe, 1 patient) Neutrophilia (1 patient) Nausea (1 patient) Vomiting (1 patient) |
10 g multiple, intravenous Dose: 10 g Route: intravenous Route: multiple Dose: 10 g Sources: |
unhealthy |
Other AEs: Drowsiness... |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Vomiting | 1 patient | 0.5 g 3 times / day multiple, oral Studied dose Dose: 0.5 g, 3 times / day Route: oral Route: multiple Dose: 0.5 g, 3 times / day Sources: |
unhealthy, 2 year |
| Hemorrhage | grade 5, 1 patient | 0.5 g 3 times / day multiple, oral Studied dose Dose: 0.5 g, 3 times / day Route: oral Route: multiple Dose: 0.5 g, 3 times / day Sources: |
unhealthy, 2 year |
| White blood cell increased | grade 5, 1 patient | 0.5 g 3 times / day multiple, oral Studied dose Dose: 0.5 g, 3 times / day Route: oral Route: multiple Dose: 0.5 g, 3 times / day Sources: |
unhealthy, 2 year |
| Nausea | 1 patient | 10 % multiple, topical |
unhealthy, 21 years |
| Vomiting | 1 patient | 10 % multiple, topical |
unhealthy, 21 years |
| Hemorrhage | grade 5, 1 patient | 10 % multiple, topical |
unhealthy, 21 years |
| Leukopenia | grade 5, 1 patient | 10 % multiple, topical |
unhealthy, 21 years |
| Liver injury | grade 5, 1 patient | 10 % multiple, topical |
unhealthy, 21 years |
| Renal disorder NOS | grade 5, 1 patient | 10 % multiple, topical |
unhealthy, 21 years |
| Leukopenia | 1 patient | 6 g 1 times / day multiple, oral Studied dose Dose: 6 g, 1 times / day Route: oral Route: multiple Dose: 6 g, 1 times / day Sources: |
unhealthy, 51-76 years Health Status: unhealthy Age Group: 51-76 years Sex: M+F Sources: |
| Nausea | 1 patient | 6 g 1 times / day multiple, oral Studied dose Dose: 6 g, 1 times / day Route: oral Route: multiple Dose: 6 g, 1 times / day Sources: |
unhealthy, 51-76 years Health Status: unhealthy Age Group: 51-76 years Sex: M+F Sources: |
| Neutrophilia | 1 patient | 6 g 1 times / day multiple, oral Studied dose Dose: 6 g, 1 times / day Route: oral Route: multiple Dose: 6 g, 1 times / day Sources: |
unhealthy, 51-76 years Health Status: unhealthy Age Group: 51-76 years Sex: M+F Sources: |
| Vomiting | 1 patient | 6 g 1 times / day multiple, oral Studied dose Dose: 6 g, 1 times / day Route: oral Route: multiple Dose: 6 g, 1 times / day Sources: |
unhealthy, 51-76 years Health Status: unhealthy Age Group: 51-76 years Sex: M+F Sources: |
| Anorexia | 4 patients | 6 g 1 times / day multiple, oral Studied dose Dose: 6 g, 1 times / day Route: oral Route: multiple Dose: 6 g, 1 times / day Sources: |
unhealthy, 51-76 years Health Status: unhealthy Age Group: 51-76 years Sex: M+F Sources: |
| Weight loss | severe, 1 patient | 6 g 1 times / day multiple, oral Studied dose Dose: 6 g, 1 times / day Route: oral Route: multiple Dose: 6 g, 1 times / day Sources: |
unhealthy, 51-76 years Health Status: unhealthy Age Group: 51-76 years Sex: M+F Sources: |
| Drowsiness | slight | 10 g multiple, intravenous Dose: 10 g Route: intravenous Route: multiple Dose: 10 g Sources: |
unhealthy |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Enzyme-induced biodegradation of polycarbonate polyurethanes: dependence on hard-segment concentration. | 2001-09-15 |
|
| Excitatory stimulation of neurons in the arcuate nucleus inhibits gastric acid secretion via vagal pathways in anesthetized rats. | 2001-09-14 |
|
| Discrete regions in the laterodorsal tegmental area of the rat regulating the urinary bladder and external urethral sphincter. | 2001-09-07 |
|
| Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis. | 2001-09-06 |
|
| GDNF improves cerebellar Purkinje neuron function in aged F344 rats. | 2001-09-01 |
|
| The release of spinal prostaglandin E2 and the effect of nitric oxide synthetase inhibition during strychnine-induced allodynia. | 2001-09 |
|
| Abrogation of alpha-adrenergic vasoactivity in chronically inflamed rat knee joints. | 2001-09 |
|
| The application of magnetic resonance microimaging to the visible light curing of dental resins. 3. Stray-field nuclear magnetic resonance imaging (STRAFI). | 2001-09 |
|
| In vitro comparison of cuspal fracture resistances of posterior teeth restored with various adhesive restorations. | 2001-08-18 |
|
| Indomethacin reduces lung adenoma number in A/J mice. | 2001-08-11 |
|
| Extracellular signal-regulated kinases 1 and 2 phosphorylated neurons in the tele- and diencephalon of rat after visceral pain stimulation: an immunocytochemical study. | 2001-08-10 |
|
| Shear bond strength of denture reline polymers to denture base polymers. | 2001-08-04 |
|
| Clinical wear performance of eight experimental dental composites over three years determined by two measuring methods. | 2001-08 |
|
| Capillary zone electrophoresis for the characterization of latex particles. | 2001-08 |
|
| Anesthetic induction agents, sympathetic nerve activity and baroreflex sensitivity: a study in rabbits comparing thiopental, propofol and etomidate. | 2001-08 |
|
| Cardiovascular effects of the methanol and dichloromethanol extracts from Mentha suaveolens Ehrh. | 2001-08 |
|
| Involvement of a urethane-sensitive system in timing the onset of gastrulation in Xenopus laevis embryos. | 2001-08 |
|
| Effects of anesthesia on cystometry and leak point pressure of the female rat. | 2001-07-27 |
|
| Macroporous copolymer matrix. IV. Expanded bed adsorption application. | 2001-07-13 |
|
| Anesthesia alters NO-mediated functional hyperemia. | 2001-07-13 |
|
| Fine chromosomal localization of the mouse Par2 gene that confers resistance against urethane-induction of pulmonary adenomas. | 2001-07-05 |
|
| Utilization of an intramolecular hydrogen bond to increase the CNS penetration of an NK(1) receptor antagonist. | 2001-07-05 |
|
| Preferential acetazolamide-induced vasodilation based on vessel size and organ: confirmation of peripheral vasodilation with use of colored microspheres. | 2001-07 |
|
| Occupational hypersensitivity pneumonitis due to isocyanates: mechanisms of action and case reports in Japan. | 2001-07 |
|
| Effect of nitric oxide synthase inhibition on fos expression in the hypothalamus of female rats following central oxytocin and systemic urethane administration. | 2001-07 |
|
| Flexural behaviour of post-cured composites at oral-simulating temperatures. | 2001-07 |
|
| Denture base polymer Alldent Sinomer: mechanical properties, water sorption and release of residual compounds. | 2001-07 |
|
| Use of a simplified method of optical recording to identify foci of maximal neuron activity in the somatosensory cortex of white rats. | 2001-06-05 |
|
| Delayed-type hypersensitivity and humoral immunity modulation by dietary lipids in a murine model of pulmonary tumorigenesis induced by urethan. | 2001-06 |
|
| Azo-containing urethane analogues for colonic drug delivery: synthesis, characterization and in-vitro evaluation. | 2001-06 |
|
| Copper(II) catalysis in cyanide conversion into ethyl carbamate in spirits and relevant reactions. | 2001-06 |
|
| Topical bicuculline to the rat spinal cord induces highly localized allodynia that is mediated by spinal prostaglandins. | 2001-06 |
|
| Sympathetic nerve and cardiovascular responses to chemical activation of the midbrain defense region. | 2001-06 |
|
| Muscarinic dependence of nucleus basalis induced conditioned receptive field plasticity. | 2001-05-25 |
|
| [Liver angiosarcoma in humans: epidemiologic considerations]. | 2001-05-23 |
|
| 2-Chloroacetaldehyde induces epsilondA DNA adducts in DNA of Raji cells as demonstrated by an improved HPLC-fluorimetry method. | 2001-05 |
|
| An in vitro wear study of posterior denture tooth materials on human enamel. | 2001-05 |
|
| Optimization of an exogenous metabolic activation system for FETAX. II. Preliminary evaluation. | 2001-05 |
|
| Adrenomedullin acts in the rat paraventricular nucleus to decrease blood pressure. | 2001-05 |
|
| The role of alpha(1)-adrenoceptors and 5-HT(1A) receptors in the control of the micturition reflex in male anaesthetized rats. | 2001-05 |
|
| Telomerase activation and p53 mutations in urethane-induced A/J mouse lung tumor development. | 2001-05 |
|
| Two unusual glycerophospholipids from a filamentous fungus, Absidia corymbifera. | 2001-04-30 |
|
| Stimulatory effects of centrally injected kappa-opioid receptor agonists on gastric acid secretion in urethane-anesthetized rats. | 2001-04-27 |
|
| A novel traceless resin-bound guanidinylating reagent for secondary amines to prepare N,N-disubstituted guanidines. | 2001-04-19 |
|
| Monoclonal antibody to rat galanin: production, characterization, and in vivo immunoneutralization activity. | 2001-04 |
|
| The effects of moisture on the dielectric relaxation of urethane dimethacrylate polymer and composites. | 2001-04 |
|
| Modulation of diaspirin crosslinked hemoglobin induced systemic and regional hemodynamic response by ethanol in normal rats. | 2001-02-09 |
|
| Differences in parasympathetic vasodilator and salivary responses in the cat submandibular gland between lingual and chorda-lingual nerve stimulation. | 2001-02 |
|
| A role of proton transfer in peroxidase-catalyzed process elucidated by substrates docking calculations. | 2001 |
|
| [A plastic property in the change of rat muscle potentials clarified in the presence of neostigmine: a conjecture on the recycling process of ACh]. | 2001 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2188890
In the 1940s, ethyl carbamate was used in man at doses of 1 g/person/day
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28818685
HepG2 cells were cultured in DMEM medium containing 10% fetal bovine serum and 1% mixture of penicillin
(100 IU/ml) and streptomycin (100g/ml) at 37 °C in the presence of 5% CO2. Cells at 80% confluent were treated with 100 mM (dissolved in DMEM medium) for different times and cell viability and mortality were timely examined. Cells without EC (Urethane) treatment were grown at the same time as control. For metabolomics and transcriptomic analyses, cells were collected at 4 h and 12 h after treatment, respectively, digested with trypsin and centrifuged in 2 mL Eppendorf tubes at 1000 rpm for 5 min in 4 °C. The cell pellets were washed with ice-cold PBS solution twice, frozen immediately in liquid nitrogen and stored at −80 °C until analysis.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 09:16:41 GMT 2025
by
admin
on
Wed Apr 02 09:16:41 GMT 2025
|
| Record UNII |
3IN71E75Z5
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C45176
Created by
admin on Wed Apr 02 09:16:41 GMT 2025 , Edited by admin on Wed Apr 02 09:16:41 GMT 2025
|
||
|
CFR |
21 CFR 216.24
Created by
admin on Wed Apr 02 09:16:41 GMT 2025 , Edited by admin on Wed Apr 02 09:16:41 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
3IN71E75Z5
Created by
admin on Wed Apr 02 09:16:41 GMT 2025 , Edited by admin on Wed Apr 02 09:16:41 GMT 2025
|
PRIMARY | |||
|
100000076664
Created by
admin on Wed Apr 02 09:16:41 GMT 2025 , Edited by admin on Wed Apr 02 09:16:41 GMT 2025
|
PRIMARY | |||
|
m11329
Created by
admin on Wed Apr 02 09:16:41 GMT 2025 , Edited by admin on Wed Apr 02 09:16:41 GMT 2025
|
PRIMARY | Merck Index | ||
|
Ethyl carbamate
Created by
admin on Wed Apr 02 09:16:41 GMT 2025 , Edited by admin on Wed Apr 02 09:16:41 GMT 2025
|
PRIMARY | |||
|
5641
Created by
admin on Wed Apr 02 09:16:41 GMT 2025 , Edited by admin on Wed Apr 02 09:16:41 GMT 2025
|
PRIMARY | |||
|
SUB11388MIG
Created by
admin on Wed Apr 02 09:16:41 GMT 2025 , Edited by admin on Wed Apr 02 09:16:41 GMT 2025
|
PRIMARY | |||
|
200-123-1
Created by
admin on Wed Apr 02 09:16:41 GMT 2025 , Edited by admin on Wed Apr 02 09:16:41 GMT 2025
|
PRIMARY | |||
|
51-79-6
Created by
admin on Wed Apr 02 09:16:41 GMT 2025 , Edited by admin on Wed Apr 02 09:16:41 GMT 2025
|
PRIMARY | |||
|
D014520
Created by
admin on Wed Apr 02 09:16:41 GMT 2025 , Edited by admin on Wed Apr 02 09:16:41 GMT 2025
|
PRIMARY | |||
|
CHEMBL462547
Created by
admin on Wed Apr 02 09:16:41 GMT 2025 , Edited by admin on Wed Apr 02 09:16:41 GMT 2025
|
PRIMARY | |||
|
DTXSID9021427
Created by
admin on Wed Apr 02 09:16:41 GMT 2025 , Edited by admin on Wed Apr 02 09:16:41 GMT 2025
|
PRIMARY | |||
|
2555
Created by
admin on Wed Apr 02 09:16:41 GMT 2025 , Edited by admin on Wed Apr 02 09:16:41 GMT 2025
|
PRIMARY | |||
|
17967
Created by
admin on Wed Apr 02 09:16:41 GMT 2025 , Edited by admin on Wed Apr 02 09:16:41 GMT 2025
|
PRIMARY | |||
|
C920
Created by
admin on Wed Apr 02 09:16:41 GMT 2025 , Edited by admin on Wed Apr 02 09:16:41 GMT 2025
|
PRIMARY | |||
|
DB04827
Created by
admin on Wed Apr 02 09:16:41 GMT 2025 , Edited by admin on Wed Apr 02 09:16:41 GMT 2025
|
PRIMARY | |||
|
3IN71E75Z5
Created by
admin on Wed Apr 02 09:16:41 GMT 2025 , Edited by admin on Wed Apr 02 09:16:41 GMT 2025
|
PRIMARY | |||
|
1329
Created by
admin on Wed Apr 02 09:16:41 GMT 2025 , Edited by admin on Wed Apr 02 09:16:41 GMT 2025
|
PRIMARY | |||
|
746
Created by
admin on Wed Apr 02 09:16:41 GMT 2025 , Edited by admin on Wed Apr 02 09:16:41 GMT 2025
|
PRIMARY | |||
|
1420982
Created by
admin on Wed Apr 02 09:16:41 GMT 2025 , Edited by admin on Wed Apr 02 09:16:41 GMT 2025
|
PRIMARY | RxNorm |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
METABOLITE -> PARENT |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|